INS and Hypoglycemia: Our data collected from a real‐world clinical setting show that patients who switched to Gla‐300 had better persistence and an associated lower risk of hypoglycaemia compared with patients who switched to other basal insulins; both treatments showed comparable glycaemic control in the subset of patients with available data.